Analyse Generate Biomedicines, Inc. (GENB) — Kairos Score 59/100

À propos de Generate Biomedicines, Inc.

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.

Informations clés

🕴️ Activité des initiés (90 jours)

1 transactions — 0 achats et 1 ventes déclarés par les dirigeants de Generate Biomedicines, Inc..

🏦 Hedge Funds

16 fonds institutionnels déclarent une position sur GENB dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur GENB.

• Zealand Pharma pens $1.2bn AI obesity drug discovery pact with Generate
• Generate Biomedicines Lands Major AI Drug Partnership to Target Booming Obesity Market

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.